1.Three Cases of Somatoform Disorder Considered as "Hontonki" Disease, Successfully Treated with Keishikakeito
Takeharu CHIJIWA ; Takashi ITO ; Masataka SUGAO ; Shoko SENDA ; Ken OKAWARA ; Shigeru EBISAWA ; Takeshi OUJI ; Hirohumi SHIMADA
Kampo Medicine 2010;61(6):840-846
We report three cases with somatoform disorder which were considered as “Hontonki” disease, successfully treated with keishikakeito. Case1 was a 34-year old male who was suffering from headache and palpitation. He said ‘Something pierces and it goes up from the chest to the head.' We considered his complaint as Hontonki disease and administered keishikakeito. After one week, the headache disappeared and four weeks later, palpitation and tinnitus were definitely improved. Case2 was a 22-year old male. His complaints were excessive strain and general fatigue. Because he had coldness of lower extremities and spasmodic headache, we interpreted these symptoms Hontonki disease and administered keishikakeito. After that these symptoms and his psychological test scores improved markedly. Case 3 was a 75-year old female. Severe headache and palpitations presented after remodeling her home. Three weeks later taking keishikakeito, her symptoms had disappeared dramatically. Recently, Hontonki disease are often compared with panic disorder, and it is possible that some somatoform disorder cases include Hontonki disease. It is important to consider the possibility of Hontonki disease behind the physical complaints such as headache and palpitation, when we use keishikakeito.
2.Validation of the Japanese Version of the STOP-Bang Test for the Risk Assessment of Obstructive Sleep Apnea Syndrome
Hideto OSHITA ; Hiroshi FUCHITA ; Noriaki ITO ; Misato SENOO ; Shoko ISOYAMA ; Yutaro YAMAMOTO ; Ayaka YOSHIDA ; Keiko OSAKI ; Kohei KAWASAKI ; Ken OKUSAKI
An Official Journal of the Japan Primary Care Association 2019;42(1):26-31
Objective: The objective of this study was to validate the Japanese version of the STOP-Bang test for risk assessment of obstructive sleep apnea syndrome (OSAS).Methods: We retrospectively evaluated inpatients who underwent nocturnal pulse oximetry for OSAS screening at the internal medical wards.Results: One hundred and forty-four subjects were included the study, and 57 subjects who had a 3% oxygen desaturation index ≥10/hr underwent polysomnography. Seventeen and 29 subjects were diagnosed with moderate and severe OSAS, respectively. According to the receiver operating characteristic (ROC) curve analysis, the STOP-Bang test had a higher diagnostic value using a cutoff of 30 kg/m2 for BMI than using a cutoff of 35 kg/m2. A STOP-Bang score of 3 or greater had a sensitivity of 95.7% and specificity of 42.9% for detecting moderate-to-severe OSAS.Conclusion: The STOP-Bang test is a simple and useful tool for the risk assessment of OSAS.
3.Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus.
Tomoyoshi SHIBUYA ; Keiichi HAGA ; Masato KAMEI ; Koki OKAHARA ; Shoko ITO ; Masahito TAKAHASHI ; Osamu NOMURA ; Takashi MURAKAMI ; Masae MAKINO ; Tomohiro KODANI ; Dai ISHIKAWA ; Naoto SAKAMOTO ; Taro OSADA ; Tatsuo OGIHARA ; Sumio WATANABE ; Akihito NAGAHARA
Intestinal Research 2018;16(3):484-488
Ulcerative colitis (UC) is 1 of the 2 major phenotypes of chronic inflammatory bowel disease (IBD), which afflicts millions of individuals throughout the world with debilitating symptoms that impair function and quality of life. Further, IBD often affects women during childbearing age. Indeed, UC activity frequently increases during pregnancy, and the medications used to induce remission may adversely affect the health of the mother and the unborn child. We report successful induction of a remission in a UC case who experienced a flare-up in the first trimester of pregnancy. Upon relapse, she was treated with steroids and adsorptive granulomonocytapheresis (GMA) with the Adacolumn plus tacrolimus. This combination therapy induced a stable remission that was maintained during her entire pregnancy. She gave birth to a healthy child at 36 weeks of pregnancy with no maternal or fetal complications. Our experience indicates that GMA, as a non-drug therapeutic intervention with a favorable safety profile, plus tacrolimus might be a relevant treatment option for patients with active IBD during pregnancy. A future study of a large cohort of pregnant patients should strengthen our findings.
Child
;
Cohort Studies
;
Colitis, Ulcerative*
;
Female
;
Humans
;
Inflammatory Bowel Diseases
;
Mothers
;
Parturition
;
Phenotype
;
Pregnancy Trimester, First
;
Pregnancy*
;
Quality of Life
;
Recurrence
;
Steroids
;
Tacrolimus*
;
Ulcer*